

37. (NEW) A method for manufacturing a medicinal product capable of inducing passive immunization comprising producing at least one monoclonal anti-NS1 antibody having a high affinity for NS1 protein in hexameric form, purifying the monoclonal antibody, and modifying the monoclonal antibody by selecting for Fab fragments or humanizing the monoclonal antibody, wherein the hexameric form is nondegraded.

38. (NEW) A method for selecting, *in vitro*, specific anti-NS1 antibodies able to diagnose an infection with a flavivirus, at an early stage, comprising binding the antibodies to NS1 protein in hexameric form, the hexameric form being nondegraded.

39. (NEW) An immunogenic composition, comprising an active principle and a pharmaceutical vehicle, wherein the active principle is either a polynucleotide capable of expressing all or part of an NS1 protein of a dengue virus of any serotype, or the active principle is an expression system comprising at least one promoter capable of expressing, in a host into which it is injected, a DNA encoding an NS1 protein of a dengue virus of any serotype.

40. (NEW) A method for expressing a polynucleotide encoding an NS1 protein of a dengue virus, comprising associating a polynucleotide of SEQ ID No. 1 with a promoter for said polynucleotide, and expressing the polynucleotide in a eukaryotic cell.

REMARKS

Entry of this Preliminary Amendment is respectfully requested.

The amendment to the specification adds sequence identifiers, and therefore does not add new matter. The substitute Sequence Listing is submitted in accordance with 37 C.F.R. § 1.825 and does not add new matter. A computer readable form of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Sequence Listing is also submitted herewith, and contains the same information as the substitute Sequence Listing.

New claims 21-40 are derived from the subject matter of original claims 1-20.

The new claims were drafted to conform to United States patent practice. These new claims do not add new matter.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 21, 2002

By: 

Kenneth J. Meyers

Reg. No. 25,146

Phone: (202) 408-4000

Fax: (202) 408-4400

Email: Ken.Meyers@finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Appendix to the Preliminary Amendment of June 21, 2002**IN THE SPECIFICATION**

Please amend the second paragraph on page 16, lines 21-24, with the following paragraph:

Figure 2 represents the sequence of the NS1 protein of dengue virus serotype 1 (SEQ ID NO: 1), obtained with clone 4C of Example 2 below, and also the corresponding coding sequence (SEQ ID NO: 2).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com